Search
Element Search
Structure Search
Thermo Scientific Chemicals
Pyruvic aldehyde, 35-45% w/w aq. soln
CAS: 78-98-8 | C3H4O2 | 72.06 g/mol
Have Questions?
Change view
Catalog number B24664.36
also known as B24664-36
Price (TWD)
-
Quantity:
500 g
Specifications
Beilstein906750
CAS78-98-8
ChEBICHEBI:17158
Chemical Name or MaterialPyruvic aldehyde
Concentration or Composition (by Analyte or Components)35 to 45% w/w aq. soln
View more
Pyruvic aldehyde is used in the synthesis and cytotoxicity evaluation of N-terminal analogues of tubulysin-U an antimitotic compound. Also used in the synthesis of imidazoles as potent calcitonin gene-related CGRP antagonists.
This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
Applications
Pyruvic aldehyde is used in the synthesis and cytotoxicity evaluation of N-terminal analogues of tubulysin-U an antimitotic compound. Also used in the synthesis of imidazoles as potent calcitonin gene-related CGRP antagonists.
Solubility
Soluble in DMSO, water.
Notes
Air sensitive. Store under dry inert gas. Store away from oxidizing agents, air.
Pyruvic aldehyde is used in the synthesis and cytotoxicity evaluation of N-terminal analogues of tubulysin-U an antimitotic compound. Also used in the synthesis of imidazoles as potent calcitonin gene-related CGRP antagonists.
Solubility
Soluble in DMSO, water.
Notes
Air sensitive. Store under dry inert gas. Store away from oxidizing agents, air.
RUO – Research Use Only
General References:
- Paul J Beisswenger; Keith S Drummond; Robert G Nelson; Scott K Howell; Benjamin S Szwergold; Michael Mauer. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes. 2005, 54 (11), 3274-3281.
- Katrien H J Gaens; Coen D A Stehouwer; Casper G Schalkwijk. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. Current Opinion in Lipidology. 2013, 24 (1), 4-11.